Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-02-13
2007-02-13
Yaen, Christopher H. (Department: 1643)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S300000
Reexamination Certificate
active
09569698
ABSTRACT:
The present invention is directed to compositions and methods for selective induction of apoptosis in cancer cells, particularly malignant cancer cells, by delivery of a IL-1α propiece polypeptide (e.g., a native IL-1α propiece polypeptide, including IL-1α propiece polypeptide variant) to a cancer cell.
REFERENCES:
patent: 4770781 (1988-09-01), Schmidt et al.
patent: 4801686 (1989-01-01), Kronheim
patent: 4894333 (1990-01-01), Cerretti et al.
patent: 5017692 (1991-05-01), Zurwarski et al.
patent: 5266311 (1993-11-01), Cerretti et al.
patent: 5494663 (1996-02-01), Yamada et al.
patent: 5702698 (1997-12-01), Nakai et al.
patent: 0 188 920 (1986-07-01), None
patent: 188920 (1986-07-01), None
patent: 0 200 986 (1986-11-01), None
patent: 0 324 447 (1989-07-01), None
patent: 32447 (1989-07-01), None
patent: 0 327 360 (1989-08-01), None
Lomedico PT.
Wessendorf et al (J. Biol. Chem. 1993;268(29):22100-22104).
Chaplin, et al. “Expression of Membrane-Associated Murine Interleukin-1 (IL-1) by Fibroblasts Transfected with Pro-IL-1α cDNA,”FASEB2(5):Abstract 5517 (May 1-5, 1988).
Higgins, et al., “Synthesis and Biological Activity of Human IL-1β Propiece In Vitro,”Arthritis and Rheumatism,36(9):Abstract B71 (Sep. 1993).
Stevenson, et al., “The N-Terminal 16kDA Propiece of the Interleukin-1α Precursor Persists Intracellularly and is Myristylated on Internal Lysine Residues,”Clinical Research,40(2):Abstract p. 186A (May 1992).
Turck, et al., “The N-Terminal Propiece of Interleukin-1α is a Pro-Apoptotic Factor,”JASN,6(3):Abstract 2052 (Sep. 1995).
Auron, et al., “Studies on the Molecular Nature of Human Interleukin-1,”J. of Immunol.,138(5):1447-1456 (Mar. 1, 1987).
Brody, et al., “Membrane IL-1: IL-1α Precursor Binds to the Plasma Membrane Via a Lectin-Like Interaction,”J. of Immunol.,143(4):1183-1187 (Aug. 15, 1989).
Cameron, et al. “Purification to Homogeneity and Amino Acid Sequence Analysis of Two Anionic Species of Human Interleukin 1,”J. Exp. Med.,164(1):237-250 (Jul. 1986).
Dixon, et al., “Apoptosis: Its Role in the Development of Malignancies and Its Potential as a Novel Therapeutic Target,”The Annals of Pharmacotherapy,31:76-82 (Jan. 1997).
Duvall, et al., “Death and the Cell,”Immunol. Today,7:115-119 (1986).
Gerschenson, et al., “Apoptosis: a Different Type of Cell Death,”FASEB,, 6-2450-2455 (Apr. 1992).
Graves, Bradford J., et al., “Structure of Interleukin 1α at 2.7-Å Resolution”,Biochemistry(1990) 29:2679-2684.
Guchelear, et al., “Apoptosis: Molecular Mechanics and Implications for Cancer Chemotherapy,”Pharmacy World&Science,19(3):119-125 (1997).
Kavita, et al., “Differential Sensitivity of Interleukin-1α and -β Precursor Proteins to Cleavage by Calpain, a Calcium-Dependent Protease,”The J. of Biol. Chem.,270(40):27758-27765 (Nov. 17, 1995).
Kronheim, et al., “Human Interleukin 1,”J. Exp. Med.,161:490-502 (Mar. 1985).
Lomedico, et al., “Cloning and Expression of Murine Interleukin-1 cDNA inEscherichia coli,” Nature,312:458-462 (Nov. 1984).
March, et al., “Cloning, Sequence and Expression of Two Distinct Human Interleukin-1 Complimentary DNA's,”Nature,315:(Jun. 1985).
Mayer, et al., “Programmed Cell Death: Will it Become a Factor in Cancer Prevention?,”Euro. J. of Cancer Prevention,6:323-329 (1997).
Mosley, et al., “The Interleukin-1 Receptor Binds the Human Interleukin-1α Precursor but Not the Interleukin-1β Precursor,”J. of Biol. Chem.,262(7):2941-2944 (Mar. 5, 1987).
Mosley, et al., “Determination of the Minumum Polypeptide Lengths of the Functionality Active Sites of Human Interleukins 1α and 1β,”Proc. Nat'l. Acad. Sci.,84:4572-4576 (Jul. 1987).
Siders, et al., Characterization of the Structural Requirements and Cell Type Specificity of IL-1α and IL-1β Secretion,J. of Biol. Chem.,268(29):22170-22174 (Oct. 1993).
Stevenson, et al., “The N-Terminal Propiece of Interleukin 1α is a Transforming Nuclear Oncoprotein,”Proc. Nat'l. Acad. Sci.,94:508-513 (Jan. 1997).
Stevenson, et al., “The 31-kDa Precursor of Interleukin 1α is Myristoylated on Specific Lysines Within 16-kDa N-Terminal Propiece,”Proc. Nat'l. Acad. Sci.,90:7245-7249 (Aug. 1993).
Tang, et al., “Target to Apoptosis: A Hopeful Weapon for Prostate Cancer,”The Prostate,32:284-293 (1997).
Walker, et al., “Patterns of Cell Death,”Meth. Achiev. Exp. Path.,13:18-54 (1998).
Wessendorf, et al., “Identification of a Nuclear Localization Sequence Within the Structure of the Human Interleukin-1 Aplpha Precursor,”J. Biol. Chem.268(29):22100-22104 (Oct. 15, 1993).
Zav′yalov, et al., “Receptor-Binding Properties of the Peptides Corresponding to the ACTH-Like Sequence of Human Pro-Interleukin-1α,”Immunology Letters,46:125-128 (1995).
Zsebo, K.M., et al., “Effects of Hematopoietin-1 and Interleukin 1 Activities on Early Hematopoietic Cells of the Bone Marrow”,Blood(1988) 71(4):962-968.
Lovett David H.
Pollock Allan S.
Turck Johanna
Bozicevic Field & Francis LLP
Francis Carol L.
Keddie James S.
The Regents of the University of California
Yaen Christopher H.
LandOfFree
Selective induction of cell death by delivery of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Selective induction of cell death by delivery of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selective induction of cell death by delivery of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3883191